Lassa fever has become a top-priority disease for the World Health Organisation (WHO). It is a life threatening zoonotic disease and public health burden endemic to Western Africa, first discovered in 1969. It is estimated there are 1-2 million cases and 5,000-10,000 deaths annually. The viral disease causes a variety of symptoms, with 80% of cases being asymptomatic to mild in nature, but has a mortality rate of 15-20% in those that are hospitalised. The virus is transmitted to humans from the reservoir species, the Natal multimammate mouse (M. natalensis), most commonly through the rodent’s urine, however human to human transmission is also possible. With the outbreak of Ebola in 2015, more attention is being placed on viral haemorrhagic infections and their pandemic potential. Currently, there are 21 vaccines in the preclinical stages. (Alli et. al, 2021; Arruda et. al, 2021)